Impact of XXXX PET/CT on the @entity5 : The Referring Physician's Perspective.

@entity1 @entity5 @entity3 @entity14103
UNASSIGNED: Somatostatin receptor imaging with @entity14103 PET/CT (DOTATATE) is increasingly used for managing @entity1 with @entity5 . The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of @entity5 . METHODS: A set of 2 questionnaires (pre-PET and post-PET) was sent to the referring physicians of 100 consecutive @entity1 with known or suspected @entity5 , who were evaluated with DOTATATE. Questionnaires on 88 @entity1 were returned (response rate, 88%). Referring physicians categorized the DOTATATE findings on the basis of the written PET reports as negative, positive, or equivocal for disease. The likelihood for @entity3 was scored as low, moderate, or high. The intended management before and changes as a consequence of the PET study were indicated. RESULTS: The indications for PET/CT were initial and subsequent treatment strategy assessments in 14% and 86% of @entity1 , respectively. Referring physicians reported that DOTATATE led to a change in suspicion for @entity3 in 21 @entity1 (24%; increased and decreased suspicion in 9 [10%] and 12 [14%] @entity1 , respectively). Intended management changes were reported in 53 of 88 (60%) @entity1 . Twenty @entity1 (23%) scheduled to undergo chemotherapy were switched to treatments without chemotherapy, and 6 (7%) were switched from watch-and-wait to other treatment strategies. Conversely, 5 @entity1 (6%) were switched from their initial treatment strategy to watch-and-wait. CONCLUSION: This survey of referring physicians demonstrates a substantial impact of DOTATATE on the intended management of @entity1 with @entity5 .
